ChAdOx1.85A+MVA85A
Candidate Overview
ChAdOx1.85A is a simian adenoviral vector expressing Antigen 85A. MVA85A is a modified vaccinia virus Ankara expressing Antigen 85A. The target route of administration for ChAdOx1.85A is aerosol, and intramuscular for MVA85A.
Sponsor / Lead Developer: University of Oxford
Clinical Trial Status: No Active Trials
Primary Indication: Prevention of TB disease
Other Indication(s): Prevention of Mtb infection or sustained infection and Prevention of TB recurrence
Target Population(s): Adolescents, Adults, Children, Infants, People cured of active TB, People living with HIV, People with Mtb infection, and People without Mtb infection
Target Route of Administration: Aerosol and Intramuscular
Clinical Trials
COMPLETED TRIALS |
|
| Registry Number | NCT03681860 |
| Clinical Trial Phase | Phase 2a |
| Clinical Trial Sponsor | University of Oxford |
| Primary endpoint(s) for this clinical trial | Safety |
| Immunogenicity | |
| Target population(s) for clinical trial | Adults |
| Adolescents | |
_________________________ |
|
| Registry Number | NCT01829490 |
| Clinical Trial Phase | Phase 1 |
| Clinical Trial Sponsor | University of Oxford |
| Primary endpoint(s) for this clinical trial | Safety |
| Target population(s) for clinical trial | Adults |